A placebo controlled, randomized study to examine the impact of 24-week orlistat treatment on postprandial triglyceridaemia, steatohepatitis and cardiovascular risk factors in overweight Chinese patie

Trial Profile

A placebo controlled, randomized study to examine the impact of 24-week orlistat treatment on postprandial triglyceridaemia, steatohepatitis and cardiovascular risk factors in overweight Chinese patie

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2012

At a glance

  • Drugs Orlistat (Primary)
  • Indications Dyslipidaemias; Overweight
  • Focus Pharmacodynamics
  • Sponsors Roche
  • Most Recent Events

    • 20 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top